(6-bromo-7-fluoro-2-methylimidazo[1,2-a]pyridin-3-yl)[2-(difluoromethoxy)phenyl]methanol | 1536391-78-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: (6-bromo-7-fluoro-2-methylimidazo[1,2-a]pyridin-3-yl)[2-(difluoromethoxy)phenyl]methanol
• 英文别名: (6-Bromo-7-fluoro-2-methylimidazo[1,2-a]pyridin-3-yl)-[2-(difluoromethoxy)phenyl]methanol
• CAS: 1536391-78-2
• 化学式: C₁₆H₁₂BrF₃N₂O₂
• 分子量: 401.183
• InChiKey: NRDQNNGIVPTOQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  46.8
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Imidazopyridine Derivatives as Modulators of TNF Activity
  申请人：UCB Biopharma SPRL

  公开号：US20150203486A1

  公开（公告）日：2015-07-23

  A series of imidazo[1,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

  一系列的咪唑[1,2-a]吡啶衍生物（I式），是人类TNFa活性的有效调节剂，因此对于治疗和/或预防各种人类疾病具有益处，包括自身免疫和炎症性疾病；神经和神经退行性疾病；疼痛和伤害性疾病；心血管疾病；代谢性疾病；眼部疾病；以及肿瘤性疾病。
• Treatment of autoimmune and inflammatory disorders with asymmetric TNF alpha trimers
  申请人：UCB Biopharma SPRL

  公开号：US10775385B2

  公开（公告）日：2020-09-15

  A new, stable trimeric TNFα structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNFα/TNFR1 interaction. Membrane-bound TNFα is not affected in its ability to signal through TNFR2, and thus the new structure of TNFα may be used in therapies which do not significantly raise the risk of infection or malignancy.

  本研究公开了一种新的、稳定的三聚 TNFα 结构，这种结构具有扭曲对称性，可与 TNFR1 受体结合以减弱其信号传导，可用于治疗和/或预防与可溶性 TNFα/TNFR1 相互作用有关的疾病。膜结合型 TNFα 通过 TNFR2 发出信号的能力不受影响，因此，TNFα 的新结构可用于治疗不会显著增加感染或恶性肿瘤风险的疾病。
• Methods of identifying signaling modulators of the trimeric TNFa
  申请人：UCB BIOPHARMA SRL

  公开号：US10883996B2

  公开（公告）日：2021-01-05

  The invention is in the field of TNF signalling. Compounds have been identified which are capable of modulating signalling of TNF trimers through receptors. Methods of identifying such compounds are therefore provided. The compounds themselves have utility in therapy.

  本发明属于 TNF 信号领域。已鉴定出能够通过受体调节 TNF 三聚体信号的化合物。因此，本发明提供了鉴定此类化合物的方法。这些化合物本身也可用于治疗。
• IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY
  申请人：UCB Biopharma SPRL

  公开号：EP2872508B1

  公开（公告）日：2018-08-29
• NOVEL TNF STRUCTURE FOR USE IN THERAPY
  申请人：UCB Biopharma SPRL

  公开号：EP3311168A1

  公开（公告）日：2018-04-25